Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Use of mutation analysis in endocrine neoplasia syndromes

Shern L Chew
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.9-4-362
Clin Med August 2009
Shern L Chew
Consultant Physician and Professor of Endocrine Medicine, St Bartholomew's Hospital, London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: s.l.chew@qmul.ac.uk
  • Article
  • Info & Metrics
Loading

The major benefit in the identification of gene mutations causing endocrine neoplasia syndromes has been to allow accurate and rapid diagnosis of affected family members. In particular, the focus of clinical surveillance, radiology and endocrine tests can be on only those carrying mutations.1It also allows testing of young individuals with apparently sporadic endocrine tumours, and many families with occult disease have been diagnosed and treated over the last 15 years.2Indeed, the original case description of phaeochromocytoma by Fraenkel has been shown to be due to multiple endocrine neoplasia type 2A.3Genetic studies have also defined new and clinically distinct endocrine neoplasia syndromes, for example: several familial paraganglioma syndromes resulting from mutations in the succinate dehydrogenase subunit genes4–6; multiple endocrine neoplasia type 4,7 and hyperparathyroidism-jaw tumour syndrome.8As a rule, genetic testing and interpretation of the results is easier in the autosomal dominant neoplasia syndromes, where one abnormal allele is sufficient for disease. In contrast, genetic testing in inherited metabolic syndromes (for example, congenital adrenal hyperplasia) is complex and less useful. This is partly because the metabolic syndromes are often autosomal recessive conditions where both alleles are mutated and a there is a high frequency of compound heterozygosity (where each allele carries a different mutation) or whole gene deletions. Furthermore, occult disease is unusual in the autosomal recessive metabolic syndromes, where biochemical tests will identify most affected individuals, in contrast to the frequent identification of occult neoplasia in asymptomatic carriers of familial endocrine neoplasia mutations.

From the clinician's view, the first major advances were in 1993. The identification of RET proto-oncogene mutations causing multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma was reported by Ponder's group.9In multiple endocrine neoplasia type 2A, the mutations are usually in cysteine codons and this allows very quick diagnostic testing in families with medullary thyroid cancer, phaeochromocytoma and hyperparathyroidism. Prophylactic thyroidectomy is now routine for young children carrying a RET mutation and is effective in improving the disease-free survival. RET mutation analysis has made pentagastrin-stim-ulation tests for the diagnosis of MEN2A obsolete (although pentagastrin-stimulation tests may still be helpful in follow-up of patients after resection of medullary thyroid carcinoma). The von Hippel-Lindau (VHL) disease tumour suppressor gene causing haemangioblastomas, retinal angiomas, renal cell carcinomas, bilateral phaeochromocytomas and pancreatic cysts and neuroendocrine tumours was also reported in 1993 (10). Testing for VHL syndrome in families had involved brain, renal, pancreatic and adrenal scanning, biochemical testing and retinal examination. This burden has effectively been halved by mutational analysis. The identification of the role of the VHL disease protein in the cellular response to hypoxia promises much for future medical treatments.

Multiple endocrine neoplasia type 1 is a much more complex clinical and genetic disease with a wide range of clinical manifestations. Although primary hyperparathyroidism due to multiple adenomas is common, using serum calcium as a screening test in families was insensitive and non-specific. The disease is caused by mutations in the MENIN gene. Genetic testing is complex because many types of mutation may affect the gene, but is important for confirming the diagnosis in patients with unusual or limited manifestations, especially the minority without hyperparathyroidism. Genetic testing also allows the possibility of identifying early pre-symptomatic hyperparathyroidism and using treatment with the calcium-sensing receptor agonist, cinacalcet, possibly avoiding extensive and repeated parathyroid surgery.

The main disappointment for clinicians is that, in general, the link between the genetic mutation and the clinical manifestations is very loose and is not useful in predicting outcome. However, genetic studies have led to much greater understanding of possible biological pathways to endocrine neoplasia. The hope is that this understanding may guide medical anti-tumour therapy, although the first trials of imatinib (a tyrosine kinase inhibitor, including anti-RET) in medullary thyroid carcinoma with RET activating mutations are disappointing. Another problem is how best and cost-effectively to test the many patients with familial endocrine neoplasia syndromes for tumours. Patients will need annual scans of several body parts. This represents a substantial lifetime radiation exposure if computed tomography is used. Magnetic resonance imaging is still slow, and the hope is that new magnetic imaging modalities will speed up scans without reducing diagnostic sensitivity and specificity. The finding that paragangliomas in patients with succinate dehydrogenase B subunit mutation are best identified by fluo-rodeoxyglucose positron emission tomography will help with the problem of imaging.11Such avidity for a glucose analogue potentially fits with the biology of the mutation, whereby a cellular defect in the flow sheet of Kreb's cycle respiration may lead to increased demands for glucose by alternative pathways.

  • © 2009 Royal College of Physicians

References

  1. ↵
    1. Brandi ML
    , Gagel RF, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86:5658–71.doi:10.1210/jc.86.12.5658
    OpenUrlCrossRefPubMed
  2. ↵
    1. Jimenez C
    , Cote G, Arnold A, Gagel RF. Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol Metab 2006; 91:2851–8.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Neumann HP
    , Vortmeyer A, Schmidt D et al. Evidence of MEN-2 in the original description of classic pheochromocytoma. N Engl J Med 2007; 357:1311–5.doi:10.1056/NEJMoa071407
    OpenUrlCrossRefPubMed
  4. ↵
    1. Baysal BE
    , Ferrell RE, Willett-Brozick JE et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000; 287:848–51.doi:10.1126/science.287.5454.848
    OpenUrlAbstract/FREE Full Text
    1. Niemann S
    , Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 2000; 26:268–70.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Astuti D
    , Latif F, Dallol A et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001; 69:49–54.doi:10.1086/321282
    OpenUrlCrossRefPubMed
  6. ↵
    1. Pellegata NS
    , Quintanilla-Martinez L, Siggelkow H et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A 2006; 103:15558–63.doi:10.1073/pnas.0603877103
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Carpten JD
    , Robbins CM, Villablanca A et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 2002; 32:676–80.doi:10.1038/ng1048
    OpenUrlCrossRefPubMed
  8. ↵
    1. Mulligan LM
    , Kwok JBJ, Healey CS et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363:458–60.doi:10.1038/363458a0
    OpenUrlCrossRefPubMed
    1. Latif F
    , Tory K, Gnarra J et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260:1317–20.doi:10.1126/science.8493574
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Timmers HJ
    , Kozupa A, Chen CC et al. Superiority of fluo-rodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol 2007; 25:2262–9.
    OpenUrlAbstract/FREE Full Text
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Use of mutation analysis in endocrine neoplasia syndromes
Shern L Chew
Clinical Medicine Aug 2009, 9 (4) 362-363; DOI: 10.7861/clinmedicine.9-4-362

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Use of mutation analysis in endocrine neoplasia syndromes
Shern L Chew
Clinical Medicine Aug 2009, 9 (4) 362-363; DOI: 10.7861/clinmedicine.9-4-362
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Current key developments
  • Current key developments
  • Revitalising glucocorticoids for (rheumatoid) arthritis
Show more Current Key Developments

Similar Articles

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians